Active vs. Stable Vitiligo: Defining Disease Activity and Psychosocial Burden

Segment summary: In this episode titled "Active vs. Stable Vitiligo: Defining Disease Activity and Psychosocial Burden," moderator Nada Elbuluk, MD, MSc, FAAD and panelist Susan Taylor, MD, FAAD address the clinical distinction between active and stable vitiligo, as well as the significant psychological impact of the disease.

Dr. Taylor describes active vitiligo as progressive and unstable, characterized by new or enlarging patches, confetti-like macules (1–5 mm), trichrome lesions displaying three distinct colors, Koebnerization (new lesions arising at sites of skin injury), and a red or pink border around existing patches. She uses a 3- to 12-month clinical window to assess activity, asking patients whether they have experienced any of these features. Stable disease, by contrast, is defined by the absence of new or enlarging lesions over 6 to 12 months.

This distinction is clinically meaningful, as it directly influences therapeutic selection — some interventions are appropriate only for stable disease, while active disease requires more urgent intervention. Dr. Elbuluk notes that emerging literature is helping to formalize and standardize these definitions for consistent clinical use.

The second half of the episode addresses the profound psychosocial burden of vitiligo. Research cited by Dr. Taylor demonstrates that patients with greater than 5% body surface area involvement, darker skin tones, or lesions on the face and hands experience the greatest psychological impact. Studies involving more than 300 vitiligo patients found that approximately half reported emotional or psychological effects, including low self-esteem, social isolation, anxiety, and a sense that others do not understand their experience.

Dr. Taylor also highlights two often-overlooked clinical strategies: referring patients to support groups such as the Global Vitiligo Foundation, and discussing camouflage options — including cover products and self-tanners — to improve quality of life while waiting for treatments to produce visible results. Dr. Elbuluk agrees that camouflage serves as an important bridge during the often lengthy repigmentation process.

In the next episode, "Shared Decision-Making and the Vitiligo Treatment Landscape," the panelists discuss how patient goals guide treatment selection, review the full spectrum of available therapies, and address the importance of stabilizing disease before pursuing repigmentation.

This video series is not sponsored, and has been produce independently by Dermatology Times.